Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2636-2641

  Stein, Rhona ^a   Chen, Susan ^a   Haim, Sara ^a   Goldenberg, David M ^a  

^a GARDEN STATE CANCER CENTER   (United States)

Author keywords

131I; 90Y; Animal models; Cancer; Lung carcinoma; Monoclonal antibodies; Radioimmunotherapy

Indexed keywords

MONOCLONAL ANTIBODY I 131; MONOCLONAL ANTIBODY RS 11 I 131; MONOCLONAL ANTIBODY RS 11 Y 90; MONOCLONAL ANTIBODY RS 7 I 131; MONOCLONAL ANTIBODY RS 7 Y 90; MONOCLONAL ANTIBODY Y 90; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT;

EID: 0031457988     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2636::aid-cncr39>3.0.co;2-b     Document Type: Conference Paper

References (25)

1. Mausner LF, Srivastava SC. Radionuclides for radioimmunotherapy. Med Phys 1993;20:503-9.
2. O'Donoghue JA, Bardics M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995; 36:1902-9.
3. Jowsey J, Rowland RE, Marshall JH. The deposition of the rare earths in bone. Radiation Res 1958;8:490-501.
4. Kozak RW, Raubitschek A, Mirzadeh S, Brechbiel MW, Junghaus R, Gansow OA, et al. Nature of bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Cancer Res 1989;49:2639-44.
5. Kyriakos RJ, Shih LB, Ong GL, Patel K, Goldenberg DM, Mattes MJ. The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 1992;52:835-42.
6. Mattes MJ, Griffiths GL, Diril H, Goldenberg DM, Ong GL, Shih LB. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer 1994;73:787-93.
7. Harapanhalli RS, Schafranek W, Ong GL, Mattes MJ. Lysine-directed radioiodination of proteins with a cyanuric chloride derivative of aminofluorescein. Anal Biochem 1995;231:50-6.
8. Geissler F, Anderson SK, Venkatesan P, Press O. Intracellular catabolism of radiolabeled anti-m antibodies by malignant B-cells. Cancer Res 1992;52:2907-15.
9. Vaes G. Digestive capacity of lysosomes. In: Hers HG, Van Hoof F, editors. Lysosomes and storage diseases. New York: Academic Press, 1973:43-77.
10. LaBadie JH, Chapman KP, Aronson NN Jr. Glycoprotein catabolism in rat liver. Lysosomal digestion of iodinated asialofetuin. Biochem J 1975;152:271-9.
11. Thorpe SR, Baynes JW, Chroneos ZC. The design and application of residualizing labels for studies on protein catabolism. FASEB J 1993;7:399-405.
12. Stein R, Goldenberg DM, Thorpe SR, Mattes MJ. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors. Cancer Res 1995;55:3132-9.
13. Stein R, Chen S, Sharkey RM, Goldenberg DM. Murine monoclonal antibodies raised: against human non-small cell carcinoma of the lung: specificity and tumor targeting. Cancer Res 1990;50:1330-6.
14. McConahey PJ, Dixon FJ. A method of trace iodination of proteins for immunologic studies. Int Arch Allergy Immunol 1966;29:185-9.
15. Motta-Hennessy C, Sharkey RM, Goldenberg DM. Metabolism of indium-111-labeled murine monoclonal antibody in tumor and normal tissue of the athymic mouse. J Nucl Med 1990;31:1510-9.
16. Cummins CH, Rutter EW Jr., Fordyce WA. A convenient synthesis of bifunctional chelating agents based on diethylenetriamine pentaacetic acid and their coordination chemistry with yttrium (III). Bioconjug Chem 1991; 2:180-6.
17. Brechbiel MW, Gansow OA, Atcher RW, Schlom RW, Esteban J, Simpson DE, et al. Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA: antibody labeling and tumor-imaging studies. Inorg Chem 1986;25:2772-81.
18. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 1984;142:68-78.
19. Sharkey RM, Blumenthal RD, Behr TM, Wong GY, Haywood L, Forman D, et al. Selection of radioimmuno conjugates for the therapy of well-established or micrometastatic colon carcinoma. Int J Cancer 1997;72:477-85.
20. Blumenthal RD, Sharkey RM, Natale AM, Kashi R, Wong G, Goldenberg DM. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res 1994;54:142-51.
21. 131I-labeled monoclonal antibody RS7-3G11. Antibody Immunoconj Radiopharm 1991;4:703-12.
22. Stein R, Goldenberg DM, Thorpe SR, Mattes MJ. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small cell carcinoma of the lung. J Nucl Med. 1997;38:391-95.
23. Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegal JA, Goldenberg DM. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res 1990;50:2330-6.
24. 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts. Int J Radiat Oncol Biol Phys 1993;25:629-38.
25. De Leij L, Helfrich W, Stein R, Mattes MJ. SCLC-Cluster-2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2. Int J Cancer 1994;8(Suppl):60-3.